{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:59:14Z","timestamp":1787900354527,"version":"build-2784847793"},"reference-count":204,"publisher":"Bentham Science Publishers Ltd.","issue":"1","funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["075-15-2022-304"],"award-info":[{"award-number":["075-15-2022-304"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRCEP"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Current therapeutic approaches for Huntington's disease (HD) focus on symptomatic\ntreatment. Therefore, the unavailability of efficient disease-modifying medicines is a significant\nchallenge. Regarding the molecular etiology, targeting the mutant gene or advanced translational\nsteps could be considered promising strategies. The evidence in gene therapy suggests various molecular\ntechniques, including knocking down mHTT expression using antisense oligonucleotides\nand small interfering RNAs and gene editing with zinc finger proteins and CRISPR-Cas9-based\ntechniques. Several post-transcriptional and post-translational modifications have also been proposed.\nHowever, the efficacy and long-term side effects of these modalities have yet to be verified.\nCurrently, cell therapy can be employed in combination with conventional treatment and could be\nused for HD in which the structural and functional restoration of degenerated neurons can occur.\nSeveral animal models have been established recently to develop cell-based therapies using renewable\ncell sources such as embryonic stem cells, induced pluripotent stem cells, mesenchymal stromal\ncells, and neural stem cells. These models face numerous challenges in translation into clinics.\nNevertheless, investigations in Advanced Therapy Medicinal Products (ATMPs) open a promising\nwindow for HD research and their clinical application. In this study, the ATMPs entry pathway in\nHD management was highlighted, and their advantages and disadvantages were discussed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0127724328300166240510071548","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T04:15:33Z","timestamp":1716783333000},"page":"14-31","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Translational Approach using Advanced Therapy Medicinal Products for Huntington's Disease"],"prefix":"10.2174","volume":"20","author":[{"given":"Maryam Alsadat","family":"Mousavi","sequence":"first","affiliation":[{"name":"Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and\nTechnology, ACECR, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliheh","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and\nTechnology, ACECR, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Pourhamzeh","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and\nTechnology, ACECR, Tehran, Iran"},{"name":"Departments of Pathology and Medicine, UC San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehri","family":"Salari","sequence":"additional","affiliation":[{"name":"Department of Neurology, Shahid Beheshti University of Medical Science, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoo","family":"Hossein-Khannazer","sequence":"additional","affiliation":[{"name":"Gastroenterology and Liver\nDiseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of\nMedical Sciences, Tehran, Iran"},{"name":"Department of Tissue Engineering and Applied Cell Sciences, School of Advanced\nTechnologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Shpichka","sequence":"additional","affiliation":[{"name":"Institute for Regenerative\nMedicine, Sechenov University, Moscow, Russia"},{"name":"World-Class Research Center &#34;Digital Biodesign and Personalized\nHealthcare,&#34; Sechenov University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Massood","family":"Nabavi","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and\nTechnology, ACECR, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Timashev","sequence":"additional","affiliation":[{"name":"Institute for Regenerative\nMedicine, Sechenov University, Moscow, Russia"},{"name":"World-Class Research Center &#34;Digital Biodesign and Personalized\nHealthcare,&#34; Sechenov University, Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Vosough","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and\nTechnology, ACECR, Tehran, Iran"},{"name":"Experimental Cancer Medicine, Institution for Laboratory Medicine,\nKarolinska Institute, 141-83 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1093\/brain\/aww165","volume":"139","author":"Wexler A.","year":"2016","unstructured":"Wexler A.; Wild E.J.; Tabrizi S.J.; George Huntington: A legacy of inquiry, empathy and hope. Brain  2016,139(8),2326-2333","journal-title":"Brain"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"Rawlins M.D.","year":"2016","unstructured":"Rawlins M.D.; Wexler N.S.; Wexler A.R.; The prevalence of Huntington\u2019s Disease. Neuroepidemiology  2016,46(2),144-153","journal-title":"Neuroepidemiology"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1080\/13543784.2020.1804552","volume":"29","author":"Barker R.A.","year":"2020","unstructured":"Barker R.A.; Fujimaki M.; Rogers P.; Rubinsztein D.C.; Huntingtin-lowering strategies for Huntington\u2019s disease. Expert Opin Investig Drugs  2020,29(10),1125-1132","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1192\/bjo.2021.969","volume":"7","author":"van Duijn E.","year":"2021","unstructured":"van Duijn E.; Fernandes A.R.; Abreu D.; Ware J.J.; Neacy E.; Sampaio C.; Incidence of completed suicide and suicide attempts in a global prospective study of Huntington\u2019s disease. BJPsych Open  2021,7(5),e158","journal-title":"BJPsych Open"},{"key":"ref=5","year":"2017","unstructured":"European Medicines Agency Advanced therapy medicinal products  Available From:\n https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-productsoverview2017","journal-title":"European Medicines Agency Advanced therapy medicinal products"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-3338-9_1","volume":"1393","author":"Galli M.C.","year":"2016","unstructured":"Galli M.C.; ATMPs for Cancer immunotherapy: A regulatory overview. Methods Mol Biol  2016,1393,1-9","journal-title":"Methods Mol Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.2174\/1570159X20666220201100238","volume":"20","author":"Hossein-Khannazer N.","year":"2022","unstructured":"Hossein-Khannazer N.; Vosough M.; Salahi S.; Mousavi M.A.; Azizi G.; Stem cell-based and advanced therapeutic modalities for Parkinson\u2019s disease: A risk-effectiveness patient-centered analysis. Curr Neuropharmacol  2022,20(12),2320-2345","journal-title":"Curr Neuropharmacol"},{"key":"ref=8","author":"Meij P.","year":"2019","unstructured":"Meij P.; Canals J.M.; Lowery M.; Scott M.;  Advanced therapy medicinal products  2019","journal-title":"Advanced therapy medicinal products"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/B978-0-12-801893-4.00003-1","volume":"144","author":"Kay C.","year":"2017","unstructured":"Kay C.; Hayden M.R.; Leavitt B.R.; Epidemiology of huntington disease. Handb Clin Neurol  2017,144,31-46","journal-title":"Handb Clin Neurol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10038-007-0227-1","volume":"53","author":"Paradisi I.","year":"2008","unstructured":"Paradisi I.; Hern\u00e1ndez A, Arias S. Huntington disease mutation in Venezuela: Age of onset, haplotype analyses and geographic aggregation. J Hum Genet  2008,53(2),127-135","journal-title":"J Hum Genet"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1002\/mds.29228","volume":"37","author":"Medina A.","year":"2022","unstructured":"Medina A.; Mahjoub Y.; Shaver L.; Pringsheim T.; Prevalence and incidence of Huntington\u2019s disease: An updated systematic review and meta\u2010analysis. Mov Disord  2022,37(12),2327-2335","journal-title":"Mov Disord"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/nmt-2016-0008","volume":"6","author":"Baig S.S.","year":"2016","unstructured":"Baig S.S.; Strong M.; Quarrell O.W.J.; The global prevalence of Huntington\u2019s disease: A systematic review and discussion. Neurodegener Dis Manag  2016,6(4),331-343","journal-title":"Neurodegener Dis Manag"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","volume":"369","author":"Walker F.O.","year":"2007","unstructured":"Walker F.O.; Huntington\u2019s disease. Lancet  2007,369(9557),218-228","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1172\/JCI17742","volume":"111","author":"Young A.B.","year":"2003","unstructured":"Young A.B.; Huntingtin in health and disease. J Clin Invest  2003,111(3),299-302","journal-title":"J Clin Invest"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jnc.14853","volume":"151","author":"Wanker E.E.","year":"2019","unstructured":"Wanker E.E.; Ast A.; Schindler F.; Trepte P.; Schnoegl S.; The pathobiology of perturbed mutant huntingtin protein\u2013protein interactions in Huntington\u2019s disease. J Neurochem  2019,151(4),507-519","journal-title":"J Neurochem"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"Tabrizi S.J.","year":"2020","unstructured":"Tabrizi S.J.; Flower M.D.; Ross C.A.; Wild E.J.; Huntington disease: New insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol  2020,16(10),529-546","journal-title":"Nat Rev Neurol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/jgm.2641","volume":"14","author":"Dong X.","year":"2012","unstructured":"Dong X.; Zong S.; Witting A.; Lindenberg K.S.; Kochanek S.; Huang B.; Adenovirus vector\u2010based in vitro neuronal cell model for Huntington\u2019s disease with human disease\u2010like differential aggregation and degeneration. J Gene Med  2012,14(7),468-481","journal-title":"J Gene Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12041-018-0957-1","volume":"97","author":"Pandey M.","year":"2018","unstructured":"Pandey M.; Rajamma U.; Huntington\u2019s disease: The coming of age. J Genet  2018,97(3),649-664","journal-title":"J Genet"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jns.2008.09.029","volume":"276","author":"Lipe H.","year":"2009","unstructured":"Lipe H.; Bird T.; Late onset Huntington Disease: Clinical and genetic characteristics of 34 cases. J Neurol Sci  2009,276(1-2),159-162","journal-title":"J Neurol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","volume":"11","author":"Frank S.","year":"2014","unstructured":"Frank S.; Treatment of Huntington\u2019s disease. Neurotherapeutics  2014,11(1),153-160","journal-title":"Neurotherapeutics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/ajmg.a.38494","volume":"176","author":"Dickey A.S.","year":"2018","unstructured":"Dickey A.S.; La Spada A.R.; Therapy development in Huntington disease: From current strategies to emerging opportunities. Am J Med Genet A  2018,176(4),842-861","journal-title":"Am J Med Genet A"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3390\/brainsci10010043","volume":"10","author":"Kumar A.","year":"2020","unstructured":"Kumar A.; Kumar V.; Singh K.; Therapeutic advances for Huntington\u2019s disease. Brain Sci  2020,10(1),43","journal-title":"Brain Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ncl.2020.01.010","volume":"38","author":"Stahl C.M.","year":"2020","unstructured":"Stahl C.M.; Feigin A.; Medical, surgical, and genetic treatment of Huntington disease. Neurol Clin  2020,38(2),367-378","journal-title":"Neurol Clin"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"8363","DOI":"10.3390\/ijms22168363","volume":"22","author":"Kim A.","year":"2021","unstructured":"Kim A.; Lalonde K.; Truesdell A.; New avenues for the treatment of Huntington\u2019s disease. Int J Mol Sci  2021,22(16),8363","journal-title":"Int J Mol Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"CD006455","DOI":"10.1002\/14651858.CD006455.pub2","volume":"2009","author":"Mestre T.","year":"2009","unstructured":"Mestre T.; Ferreira J.; Coelho M.M.; Rosa M.; Sampaio C.; Therapeutic interventions for disease progression in Huntington\u2019s disease. Cochrane Database Syst Rev  2009,2009(3),CD006455","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mds.23953","volume":"27","author":"Venuto C.S.","year":"2012","unstructured":"Venuto C.S.; McGarry A.; Ma Q.; Kieburtz K.; Pharmacologic approaches to the treatment of Huntington\u2019s disease. Mov Disord  2012,27(1),31-41","journal-title":"Mov Disord"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"Jankovic J.","year":"2011","unstructured":"Jankovic J.; Clarence-Smith K.; Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother  2011,11(11),1509-1523","journal-title":"Expert Rev Neurother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11910-017-0739-9","volume":"17","author":"Wyant K.J.","year":"2017","unstructured":"Wyant K.J.; Ridder A.J.; Dayalu P.; Huntington\u2019s disease\u2014update on treatments. Curr Neurol Neurosci Rep  2017,17(4),33","journal-title":"Curr Neurol Neurosci Rep"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jama.2016.0970","volume":"316","author":"Frank S.","year":"2016","unstructured":"Frank S.; Effect of Deutetrabenazine on chorea among patients with huntington disease a randomized clinical trial. JAMA  2016,316(1),40-50","journal-title":"JAMA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40734-017-0051-5","volume":"4","author":"Claassen D.O.","year":"2017","unstructured":"Claassen D.O.; Carroll B.; De Boer L.M.; Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord  2017,4(1),3","journal-title":"J Clin Mov Disord"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","volume":"74","author":"Loy C.","year":"2017","unstructured":"Loy C.; Claassen D.O.; Colcher A.; Davis C.S.; Duker A.; Eberly S.W.; Safety of converting from tetrabenazine to deutetrabenazine for the treatment of Chorea. JAMA Neurol  2017,74(8),977-982","journal-title":"JAMA Neurol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/S1474-4422(23)00127-8","volume":"22","author":"Furr Stimming E.","year":"2023","unstructured":"Furr Stimming E.; Claassen D.O.; Kayson E.; Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol  2023,22(6),494-504","journal-title":"Lancet Neurol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"RRN1260","DOI":"10.1371\/currents.RRN1260","volume":"3","author":"Burgunder J.M.","year":"2011","unstructured":"Burgunder J.M.; Guttman M.; Perlman S.; Goodman N.; van Kammen D.P.; Goodman L.; An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington\u2019s disease. PLoS Curr  2011,3,RRN1260","journal-title":"PLoS Curr"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1212\/WNL.0b013e318263c443","volume":"793","author":"Armstrong M.J.","year":"2012","unstructured":"Armstrong M.J.; Evidence-based guideline: Pharmacologic treatment of chorea in Huntington disease. Neurology  2012,793(6),597-603","journal-title":"Neurology"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40265-016-0670-4","volume":"77","author":"Coppen E.M.","year":"2017","unstructured":"Coppen E.M.; Roos R.A.C.; Current pharmacological approaches to reduce chorea in Huntington\u2019s disease. Drugs  2017,77(1),29-46","journal-title":"Drugs"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00004714-199902000-00020","volume":"19","author":"Dallocchio C.","year":"1999","unstructured":"Dallocchio C.; Buffa C.; Tinelli C.; Mazzarello P.; Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol  1999,19(1),101-103","journal-title":"J Clin Psychopharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/mds.22188","volume":"23","author":"Priller J.","year":"2008","unstructured":"Priller J.; Ecker D.; Landwehrmeyer B.; Craufurd D.; A Europe\u2010wide assessment of current medication choices in Huntington\u2019s disease. Mov Disord  2008,23(12),1788","journal-title":"Mov Disord"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"s83","DOI":"10.1007\/s100720200081","volume":"23","author":"Lucetti C.","year":"2002","unstructured":"Lucetti C.; Gambaccini G.; Bernardini S.; Amantadine in Huntington\u2019s disease: Open-label video-blinded study. Neurol Sci  2002,23(0)(Suppl. 2),s83-s84","journal-title":"Neurol Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1212\/01.WNL.0000096019.71649.2B","volume":"61","year":"2003","unstructured":"Huntington Study Group. Dosage effects of riluzole in Huntington\u2019s disease. Neurology  2003,61(11),1551-1556","journal-title":"Neurology"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/ana.21181","volume":"62","author":"Landwehrmeyer G.B.","year":"2007","unstructured":"Landwehrmeyer G.B.; Dubois B.; de Y\u00e9benes J.G.; Riluzole in Huntington\u2019s disease: A 3\u2010year, randomized controlled study. Ann Neurol  2007,62(3),262-272","journal-title":"Ann Neurol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/archneur.60.7.996","volume":"60","author":"O\u2019Suilleabhain P.","year":"2003","unstructured":"O\u2019Suilleabhain P.; Dewey R.B.; A randomized trial of amantadine in Huntington disease. Arch Neurol  2003,60(7),996-998","journal-title":"Arch Neurol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2018.09.022","volume":"396","author":"Testa C.M.","year":"2019","unstructured":"Testa C.M.; Jankovic J.; Huntington disease: A quarter century of progress since the gene discovery. J Neurol Sci  2019,396,52-68","journal-title":"J Neurol Sci"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1212\/WNL.45.5.951","volume":"45","author":"Paulsen J.S.","year":"1995","unstructured":"Paulsen J.S.; Butters N.; Sadek J.R.; Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology  1995,45(5),951-956","journal-title":"Neurology"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","volume":"15","author":"Fernandez H.H.","year":"2000","unstructured":"Fernandez H.H.; Friedman J.H.; Grace J.; Beason-Hazen S.; Donepezil for Huntington\u2019s disease. Mov Disord  2000,15(1),173-176","journal-title":"Mov Disord"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","volume":"9","author":"Rot U.","year":"2002","unstructured":"Rot U.; Kobal J.; Sever A.; Pirto\u0161ek Z, Mesec A. Rivastigmine in the treatment of Huntington\u2019s disease. Eur J Neurol  2002,9(6),689-690","journal-title":"Eur J Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/mds.20235","volume":"19","author":"de Tommaso M.","year":"2004","unstructured":"de Tommaso M.; Specchio N.; Sciruicchio V.; Difruscolo O.; Specchio L.M.; Effects of rivastigmine on motor and cognitive impairment in Huntington\u2019s disease. Mov Disord  2004,19(12),1516-1518","journal-title":"Mov Disord"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004850-200401000-00010","volume":"19","author":"Petrikis P.","year":"2004","unstructured":"Petrikis P.; Andreou C.; Piachas A.; Bozikas V.P.; Karavatos A.; Treatment of Huntington??s disease with galantamine. Int Clin Psychopharmacol  2004,19(1),49-50","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","volume":"102","author":"Galts C.P.C.","year":"2019","unstructured":"Galts C.P.C.; Bettio L.E.B.; Jewett D.C.; Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neurosci Biobehav Rev  2019,102,56-84","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/B978-0-12-801893-4.00011-0","volume":"144","author":"van Duijn E.","year":"2017","unstructured":"van Duijn E.; Medical treatment of behavioral manifestations of Huntington disease. Handb Clin Neurol  2017,144,129-139","journal-title":"Handb Clin Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/mds.25980","volume":"29","author":"Moulton C.D.","year":"2014","unstructured":"Moulton C.D.; Hopkins C.W.P.; Bevan-Jones W.R.; Systematic review of pharmacological treatments for depressive symptoms in Huntington\u2019s disease. Mov Disord  2014,29(12),1556-1561","journal-title":"Mov Disord"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1034\/j.1600-0404.2002.01197.x","volume":"105","author":"Paleacu D.","year":"2002","unstructured":"Paleacu D.; Anca M.; Giladi N.; Olanzapine in Huntington\u2019s disease. Acta Neurol Scand  2002,105(6),441-444","journal-title":"Acta Neurol Scand"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1080\/10401230701844802","volume":"20","author":"Nasrallah H.A.","year":"2008","unstructured":"Nasrallah H.A.; Black D.W.; Goldberg J.F.; Muzina D.J.; Pariser S.F.; Diagnosing and managing psychotic and mood disorders. Ann Clin Psychiatry  2008,20(Suppl. 1),S1-S28","journal-title":"Ann Clin Psychiatry"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S2215-0366(16)30144-4","volume":"3","author":"Eddy C.M.","year":"2016","unstructured":"Eddy C.M.; Parkinson E.G.; Rickards H.E.; Changes in mental state and behaviour in Huntington\u2019s disease. Lancet Psychiatry  2016,3(11),1079-1086","journal-title":"Lancet Psychiatry"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/JHD-180293","volume":"7","author":"Anderson K.E.","year":"2018","unstructured":"Anderson K.E.; van Duijn E.; Craufurd D.; Clinical management of neuropsychiatric symptoms of Huntington disease: Expert-based consensus guidelines on agitation, anxiety, apathy, psychosis and sleep disorders. J Huntingtons Dis  2018,7(4),355-366","journal-title":"J Huntingtons Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","volume":"19","author":"van Duijn E.","year":"2007","unstructured":"van Duijn E.; Kingma E.M.; van der Mast R.C.; Psychopathology in verified Huntington\u2019s disease gene carriers. J Neuropsychiatry Clin Neurosci  2007,19(4),441-448","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1136\/jnnp-2013-307343","volume":"85","author":"van Duijn E.","year":"2014","unstructured":"van Duijn E.; Craufurd D.; Hubers A.A.M.; Neuropsychiatric symptoms in a European Huntington\u2019s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry  2014,85(12),1411-1418","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/s10571-020-01003-0","volume":"42","author":"Khodagholi F.","year":"2022","unstructured":"Khodagholi F.; Maleki A.; Motamedi F.; Mousavi M.A.; Rafiei S.; Moslemi M.; Oxytocin prevents the development of 3-NP-induced anxiety and depression in male and female rats: Possible interaction of OXTR and mGluR2. Cell Mol Neurobiol  2022,42(4),1105-1123","journal-title":"Cell Mol Neurobiol"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2174\/1871527315666161107093047","volume":"16","author":"Simmons D.A.","year":"2017","unstructured":"Simmons D.A.; Massa S.M.; Neurotrophin receptor signaling as a therapeutic target for Huntington\u2019s Disease. CNS Neurol Disord Drug Targets  2017,16(3),291-302","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"105642","DOI":"10.1016\/j.bioorg.2022.105642","volume":"120","author":"Devadiga S.J.","year":"2022","unstructured":"Devadiga S.J.; Bharate S.S.; Recent developments in the management of Huntington\u2019s disease. Bioorg Chem  2022,120,105642","journal-title":"Bioorg Chem"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1212\/01.WNL.0000052992.58107.67","volume":"60","author":"Wheelock V.L.","year":"2003","unstructured":"Wheelock V.L.; Tempkin T.; Marder K.; Predictors of nursing home placement in Huntington disease. Neurology  2003,60(6),998-1001","journal-title":"Neurology"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/B978-0-444-63916-5.00016-1","volume":"159","author":"Vuong K.","year":"2018","unstructured":"Vuong K.; Canning C.G.; Menant J.C.; Loy C.T.; Gait, balance, and falls in Huntington disease. Handb Clin Neurol  2018,159,251-260","journal-title":"Handb Clin Neurol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1468-1331.2012.03760.x","volume":"20","author":"Bohlen S","year":"2013","unstructured":"Bohlen S; Ekwall C; Hellstr\u00f6m K, et al. Physical therapy in H untington\u2019s disease \u2013 toward objective assessments? Eur J Neurol  2013,20(2),389-393","journal-title":"Eur J Neurol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2217\/nmt-2016-0007","volume":"6","author":"Hartmann C.J.","year":"2016","unstructured":"Hartmann C.J.; Groiss S.J.; Vesper J.; Schnitzler A.; Wojtecki L.; Brain stimulation in Huntington\u2019s disease. Neurodegener Dis Manag  2016,6(3),223-236","journal-title":"Neurodegener Dis Manag"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3171\/2014.2.JNS131722","volume":"121","author":"Gonzalez V.","year":"2014","unstructured":"Gonzalez V.; Cif L.; Biolsi B.; Deep brain stimulation for Huntington\u2019s disease: Long-term results of a prospective open-label study. J Neurosurg  2014,121(1),114-122","journal-title":"J Neurosurg"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/0192623307309925","volume":"36","author":"Cotrim A.P.","year":"2008","unstructured":"Cotrim A.P.; Baum B.J.; Gene therapy: Some history, applications, problems, and prospects. Toxicol Pathol  2008,36(1),97-103","journal-title":"Toxicol Pathol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1566523220999200716111502","volume":"20","author":"Iqubal A.","year":"2020","unstructured":"Iqubal A.; Iqubal M.K.; Khan A.; Ali J.; Baboota S.; Haque S.E.; Gene therapy, a novel therapeutic tool for neurological disorders: Current progress, challenges and future prospective. Curr Gene Ther  2020,20(3),184-194","journal-title":"Curr Gene Ther"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/sj.gt.3301119","volume":"7","author":"Costantini L.C.","year":"2000","unstructured":"Costantini L.C.; Bakowska J.C.; Breakefield X.O.; Isacson O.; Gene therapy in the CNS. Gene Ther  2000,7(2),93-109","journal-title":"Gene Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ibneur.2023.01.009","volume":"14","author":"Wijekoon N.","year":"2023","unstructured":"Wijekoon N.; Gonawala L.; Ratnayake P.; Gene therapy for selected neuromuscular and trinucleotide repeat disorders \u2013 An insight to subsume South Asia for multicenter clinical trials. IBRO Neuroscience Reports  2023,14,146-153","journal-title":"IBRO Neuroscience Reports"},{"key":"ref=69","first-page":"139","volume":"103","author":"Slade N.","year":"2001","unstructured":"Slade N.; Viral vectors in gene therapy. Period Biol  2001,103(2),139-144","journal-title":"Period Biol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrneurol.2013.56","volume":"9","author":"Simonato M.","year":"2013","unstructured":"Simonato M.; Bennett J.; Boulis N.M.; Progress in gene therapy for neurological disorders. Nat Rev Neurol  2013,9(5),277-291","journal-title":"Nat Rev Neurol"},{"key":"ref=71","first-page":"3","volume":"51","author":"Boulaiz H.","year":"2005","unstructured":"Boulaiz H.; Marchal J.A.; Prados J.; Melguizo C.; Ar\u00e1nega A. Non-viral and viral vectors for gene therapy. Cell Mol Biol  2005,51(1),3-22","journal-title":"Cell Mol Biol"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jconrel.2003.10.009","volume":"94","author":"Arnedo A.","year":"2004","unstructured":"Arnedo A.; Irache J.M.; Merodio M.; Mill\u00e1n, MS. Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotide. J Control Release  2004,94(1),217-227","journal-title":"J Control Release"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"Lv H.","year":"2006","unstructured":"Lv H.; Zhang S.; Wang B.; Cui S.; Yan J.; Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release  2006,114(1),100-109","journal-title":"J Control Release"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ijpharm.2013.11.041","volume":"459","author":"Ibraheem D.","year":"2014","unstructured":"Ibraheem D.; Elaissari A.; Fessi H.; Gene therapy and DNA delivery systems. Int J Pharm  2014,459(1-2),70-83","journal-title":"Int J Pharm"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"Yamamoto A.","year":"2000","unstructured":"Yamamoto A.; Lucas J.J.; Hen R.; Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell  2000,101(1),57-66","journal-title":"Cell"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1111\/febs.12418","volume":"280","author":"Lee C.Y.D.","year":"2013","unstructured":"Lee C.Y.D.; Cantle J.P.; Yang X.W.; Genetic manipulations of mutant huntingtin in mice: New insights into Huntington\u2019s disease pathogenesis. FEBS J  2013,280(18),4382-4394","journal-title":"FEBS J"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","volume":"26","author":"Miniarikova J.","year":"2018","unstructured":"Miniarikova J.; Evers M.M.; Konstantinova P.; Translation of microRNA-based huntingtin-lowering therapies from preclinical studies to the clinic. Mol Ther  2018,26(4),947-962","journal-title":"Mol Ther"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"Tabrizi S.J.","year":"2019","unstructured":"Tabrizi S.J.; Leavitt B.R.; Landwehrmeyer G.B.; Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med  2019,380(24),2307-2316","journal-title":"N Engl J Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"Rinaldi C.","year":"2018","unstructured":"Rinaldi C.; Wood M.J.A.; Antisense oligonucleotides: The next frontier for treatment of neurological disorders. Nat Rev Neurol  2018,14(1),9-21","journal-title":"Nat Rev Neurol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","volume":"74","author":"Kordasiewicz H.B.","year":"2012","unstructured":"Kordasiewicz H.B.; Stanek L.M.; Wancewicz E.V.; Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis. Neuron  2012,74(6),1031-1044","journal-title":"Neuron"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"Carroll J.B.","year":"2011","unstructured":"Carroll J.B.; Warby S.C.; Southwell A.L.; Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther  2011,19(12),2178-2185","journal-title":"Mol Ther"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"9634","DOI":"10.1093\/nar\/gkt725","volume":"41","year":"2013","unstructured":"\u00d8stergaard ME, Southwell AL, Kordasiewicz H, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res  2013,41(21),9634-50","journal-title":"Nucleic Acids Res"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"Be\u010danovi\u0107 K.","year":"2015","unstructured":"Be\u010danovi\u0107 K.; N\u00f8rrem\u00f8lle A.; Neal S.J.; A SNP in the HTT promoter alters NF-\u03baB binding and is a bidirectional genetic modifier of Huntington disease. Nat Neurosci  2015,18(6),807-816","journal-title":"Nat Neurosci"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","volume":"6","author":"Aguiar S.","year":"2017","unstructured":"Aguiar S.; van der Gaag B.; Cortese F.A.B.; RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA. Transl Neurodegener  2017,6(1),30","journal-title":"Transl Neurodegener"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","volume":"36","author":"Rook M.E.","year":"2022","unstructured":"Rook M.E.; Southwell A.L.; Antisense oligonucleotide therapy: From design to the Huntington disease clinic. BioDrugs  2022,36(2),105-119","journal-title":"BioDrugs"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1474-4422(22)00121-1","volume":"21","author":"Tabrizi S.J.","year":"2022","unstructured":"Tabrizi S.J.; Estevez-Fraga C.; van Roon-Mom W.M.C.; Potential disease-modifying therapies for Huntington\u2019s disease: Lessons learned and future opportunities. Lancet Neurol  2022,21(7),645-658","journal-title":"Lancet Neurol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14802\/jmd.21006","volume":"15","author":"Byun S.","year":"2022","unstructured":"Byun S.; Lee M.; Kim M.; Gene therapy for Huntington\u2019s disease: The final strategy for a cure? J Mov Disord  2022,15(1),15-20","journal-title":"J Mov Disord"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.4103\/1673-5374.310673","volume":"16","author":"Peplow P.V.","year":"2021","unstructured":"Peplow P.V.; Martinez B.; Altered microRNA expression in animal models of Huntington\u2019s disease and potential therapeutic strategies. Neural Regen Res  2021,16(11),2159-2169","journal-title":"Neural Regen Res"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3233\/JHD-200002","volume":"9","author":"Rodrigues F.B.","year":"2020","unstructured":"Rodrigues F.B.; Wild E.J.; Huntington\u2019s disease clinical trials corner: April 2020. J Huntingtons Dis  2020,9(2),185-197","journal-title":"J Huntingtons Dis"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","volume":"34","author":"Shannon K.M.","year":"2020","unstructured":"Shannon K.M.; Recent Advances in the treatment of Huntington\u2019s Disease: Targeting DNA and RNA. CNS Drugs  2020,34(3),219-228","journal-title":"CNS Drugs"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/nrd.2018.133","volume":"17","author":"Caron N.S.","year":"2018","unstructured":"Caron N.S.; Dorsey E.R.; Hayden M.R.; Therapeutic approaches to Huntington disease: From the bench to the clinic. Nat Rev Drug Discov  2018,17(10),729-750","journal-title":"Nat Rev Drug Discov"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","volume":"25","author":"Zeitler B.","year":"2019","unstructured":"Zeitler B.; Froelich S.; Marlen K.; Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington\u2019s disease. Nat Med  2019,25(7),1131-1142","journal-title":"Nat Med"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"Wild E.J.","year":"2017","unstructured":"Wild E.J.; Tabrizi S.J.; Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol  2017,16(10),837-847","journal-title":"Lancet Neurol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","volume":"46","author":"Jiang F.","year":"2017","unstructured":"Jiang F.; Doudna J.A.; CRISPR\u2013Cas9 structures and mechanisms. Annu Rev Biophys  2017,46(1),505-529","journal-title":"Annu Rev Biophys"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13238-015-0153-5","volume":"6","author":"Liang P.","year":"2015","unstructured":"Liang P.; Xu Y.; Zhang X.; CRISPR\/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell  2015,6(5),363-372","journal-title":"Protein Cell"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"ddw286","DOI":"10.1093\/hmg\/ddw286","volume":"25","author":"Shin J.W.","year":"2016","unstructured":"Shin J.W.; Kim K.H.; Chao M.J.; Permanent inactivation of Huntington\u2019s disease mutation by personalized allele-specific CRISPR\/Cas9. Hum Mol Genet  2016,25(20),ddw286","journal-title":"Hum Mol Genet"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1007\/s12035-022-03150-5","volume":"60","author":"Alkanli S.S.","year":"2023","unstructured":"Alkanli S.S.; Alkanli N.; Ay A.; Albeniz I.; CRISPR\/Cas9 mediated therapeutic approach in Huntington\u2019s disease. Mol Neurobiol  2023,60(3),1486-1498","journal-title":"Mol Neurobiol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.15252\/emmm.201707763","volume":"9","author":"Alpaugh M.","year":"2017","unstructured":"Alpaugh M.; Galleguillos D.; Forero J.; Disease\u2010modifying effects of ganglioside GM1 in Huntington\u2019s disease models. EMBO Mol Med  2017,9(11),1537-1557","journal-title":"EMBO Mol Med"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1523\/JNEUROSCI.6348-09.2010","volume":"30","author":"Maglione V.","year":"2010","unstructured":"Maglione V.; Marchi P.; Di Pardo A.; Impaired ganglioside metabolism in Huntington\u2019s disease and neuroprotective role of GM1. J Neurosci  2010,30(11),4072-4080","journal-title":"J Neurosci"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1073\/pnas.1114502109","volume":"109","author":"Di Pardo A.","year":"2012","unstructured":"Di Pardo A.; Maglione V.; Alpaugh M.; Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc Natl Acad Sci USA  2012,109(9),3528-3533","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ncpneuro0199","volume":"2","author":"Sadri-Vakili G.","year":"2006","unstructured":"Sadri-Vakili G.; Cha J.H.J.; Mechanisms of Disease: Histone modifications in Huntington\u2019s disease. Nat Clin Pract Neurol  2006,2(6),330-338","journal-title":"Nat Clin Pract Neurol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/bcp.12512","volume":"79","author":"S\u00fcssmuth S.D.","year":"2015","unstructured":"S\u00fcssmuth S.D.; Haider S.; Landwehrmeyer G.B.; An exploratory double\u2010blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington\u2019s disease. Br J Clin Pharmacol  2015,79(3),465-476","journal-title":"Br J Clin Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/cns.12834","volume":"24","author":"Cardinale A.","year":"2018","unstructured":"Cardinale A.; Fusco F.R.; Inhibition of phosphodiesterases as a strategy to achieve neuroprotection in Huntington\u2019s disease. CNS Neurosci Ther  2018,24(4),319-328","journal-title":"CNS Neurosci Ther"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","volume":"123","author":"Hebb A.L.O.","year":"2004","unstructured":"Hebb A.L.O.; Robertson H.A.; Denovan-Wright E.M.; Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington\u2032s disease transgenic mice prior to the onset of motor symptoms. Neuroscience  2004,123(4),967-981","journal-title":"Neuroscience"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/hipo.22128","volume":"23","author":"Giralt A","year":"2013","unstructured":"Giralt A; Saavedra A; Carret\u00f3n O, et al. PDE10 inhibition increases GluA1 and CREB phosphorylation and improves spatial and recognition memories in a Huntington\u2019s disease mouse model. Hippocampus  2013,23(8),684-695","journal-title":"Hippocampus"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1460-9568.2006.04590.x","volume":"23","author":"Gin\u00e9s S.","year":"2006","unstructured":"Gin\u00e9s S.; Bosch M.; Marco S.; Reduced expression of the TrkB receptor in Huntington\u2019s disease mouse models and in human brain. Eur J Neurosci  2006,23(3),649-658","journal-title":"Eur J Neurosci"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"e87923","DOI":"10.1371\/journal.pone.0087923","volume":"9","author":"Todd D.","year":"2014","unstructured":"Todd D.; Gowers I.; Dowler S.J.; A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington\u2019s disease. PLoS One  2014,9(2),e87923","journal-title":"PLoS One"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2174\/187152710793237430","volume":"9","author":"Thevandavakkam M.A.","year":"2010","unstructured":"Thevandavakkam M.A.; Schwarcz R.; Muchowski P.J.; Giorgini F.; Targeting kynurenine 3-monooxygenase (KMO): Implications for therapy in Huntington\u2019s disease. CNS Neurol Disord Drug Targets  2010,9(6),791-800","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cub.2011.04.028","volume":"21","author":"Campesan S.","year":"2011","unstructured":"Campesan S.; Green E.W.; Breda C.; The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington\u2019s disease. Curr Biol  2011,21(11),961-966","journal-title":"Curr Biol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"e0152498","DOI":"10.1371\/journal.pone.0152498","volume":"11","author":"Jia H.","year":"2016","unstructured":"Jia H.; Wang Y.; Morris C.D.; The effects of pharmacological inhibition of Histone Deacetylase 3 (HDAC3) in Huntington\u2019s Disease mice. PLoS One  2016,11(3),e0152498","journal-title":"PLoS One"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","volume":"23","author":"Ferrante R.J.","year":"2003","unstructured":"Ferrante R.J.; Kubilus J.K.; Lee J.; Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice. J Neurosci  2003,23(28),9418-9427","journal-title":"J Neurosci"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1242\/jcs.025726","volume":"121","author":"Ravikumar B.","year":"2008","unstructured":"Ravikumar B.; Imarisio S.; Sarkar S.; O\u2019Kane C.J.; Rubinsztein D.C.; Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease. J Cell Sci  2008,121(10),1649-1660","journal-title":"J Cell Sci"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.neuron.2019.12.003","volume":"105","author":"Fox L.M.","year":"2020","unstructured":"Fox L.M.; Kim K.; Johnson C.W.; Huntington\u2019s Disease pathogenesis is modified in vivo by Alfy\/Wdfy3 and selective macroautophagy. Neuron  2020,105(5),813-821.e6","journal-title":"Neuron"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-981-15-4370-8_5","volume":"1266","author":"Monk R.","year":"2020","unstructured":"Monk R.; Connor B.; Cell replacement therapy for Huntington\u2019s Disease. Adv Exp Med Biol  2020,1266,57-69","journal-title":"Adv Exp Med Biol"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.neubiorev.2017.02.017","volume":"77","author":"Tartaglione A.M.","year":"2017","unstructured":"Tartaglione A.M.; Popoli P.; Calamandrei G.; Regenerative medicine in Huntington\u2019s disease: Strengths and weaknesses of preclinical studies. Neurosci Biobehav Rev  2017,77,32-47","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1242\/dev.084608","volume":"140","author":"Carri A.D.","year":"2013","unstructured":"Carri A.D.; Onorati M.; Lelos M.J.; Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development  2013,140(2),301-312","journal-title":"Development"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1242\/dev.117093","volume":"142","author":"Arber C.","year":"2015","unstructured":"Arber C.; Precious S.V.; Cambray S.; Activin A directs striatal projection neuron differentiation of human pluripotent stem cells. Development  2015,142(7),1375-1386","journal-title":"Development"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"E1234","DOI":"10.1073\/pnas.1611473114","volume":"114","author":"Faedo A.","year":"2017","unstructured":"Faedo A.; Laporta A.; Segnali A.; Differentiation of human telencephalic progenitor cells into MSNs by inducible expression of Gsx2 and Ebf1. Proc Natl Acad Sci USA  2017,114(7),E1234-E1242","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nm0698-727","volume":"4","author":"Kendall A.L.","year":"1998","unstructured":"Kendall A.L.; Rayment F.D.; Torres E.M.; Baker H.F.; Ridley R.M.; Dunnett S.B.; Functional integration of striatal allografts in a primate model of Huntington\u2019s disease. Nat Med  1998,4(6),727-729","journal-title":"Nat Med"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0079-6123(00)27017-9","volume":"127","author":"Dunnett S.B.","year":"2000","unstructured":"Dunnett S.B.; Nathwani F.; Bj\u00f6rklund A. The integration and function of striatal grafts. Prog Brain Res  2000,127,345-80","journal-title":"Prog Brain Res"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0006-8993(86)91636-7","volume":"365","author":"Deckel A.W.","year":"1986","unstructured":"Deckel A.W.; Moran T.H.; Coyle J.T.; Sanberg P.R.; Robinson R.G.; Anatomical predictors of behavioral recovery following fetal striatal transplants. Brain Res  1986,365(2),249-258","journal-title":"Brain Res"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1073\/pnas.83.8.2728","volume":"83","author":"Isacson O.","year":"1986","unstructured":"Isacson O.; Dunnett S.B.; Bj\u00f6rklund A.; Graft-induced behavioral recovery in an animal model of Huntington disease. Proc Natl Acad Sci USA  1986,83(8),2728-2732","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/BF00243834","volume":"65","author":"Pritzel M.","year":"1986","unstructured":"Pritzel M.; Isacson O.; Brundin P.; Wiklund L.; Bj\u00f6rklund A.; Afferent and efferent connections of striatal grafts implanted into the ibotenic acid lesioned neostriatum in adult rats. Exp Brain Res  1986,65(1),112-126","journal-title":"Exp Brain Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/0306-4522(88)90068-1","volume":"24","author":"Sirinathsinghji D.J.S.","year":"1988","unstructured":"Sirinathsinghji D.J.S.; Dunnett S.B.; Isacson O.; Clarke D.J.; Kendrick K.; Bj\u00f6rklund A.; Striatal grafts in rats with unilateral neostriatal lesions\u2014II. In vivo monitoring of gaba release in globus pallidus and substantia nigra. Neuroscience  1988,24(3),803-811","journal-title":"Neuroscience"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0079-6123(08)60265-4","volume":"78","author":"Clarke D.J.","year":"1988","unstructured":"Clarke D.J.; Dunnett S.B.; Isacson O.; Bj\u00f6rklund A. Striatal grafts in the ibotenic acid-lesioned neostriatum: Ultrastructural and immunocytochemical studies. Prog Brain Res  1988,78,47-53","journal-title":"Prog Brain Res"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0306-4522(88)90067-X","volume":"24","author":"Clarke D.J.","year":"1988","unstructured":"Clarke D.J.; Dunnett S.B.; Isacson O.; Sirinathsinghji D.J.S.; Bj\u00f6rklund A.; Striatal grafts in rats with unilateral neostriatal lesions\u2014I. Ultrastructural evidence of afferent synaptic inputs from the host nigrostriatal pathway. Neuroscience  1988,24(3),791-801","journal-title":"Neuroscience"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/0306-4522(88)90069-3","volume":"24","author":"Dunnett S.B.","year":"1988","unstructured":"Dunnett S.B.; Isacson O.; Sirinathsinghji D.J.S.; Clarke D.J.; Bj\u00f6rklund A.; Striatal grafts in rats with unilateral neostriatal lesions\u2014III. Recovery from dopamine-dependent motor asymmetry and deficits in skilled paw reaching. Neuroscience  1988,24(3),813-820","journal-title":"Neuroscience"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0079-6123(08)60264-2","volume":"78","author":"Dunnett S.B.","year":"1988","unstructured":"Dunnett S.B.; Isacson O.; Sirinathsinghji D.J.S.; Clarke D.J.; Bj\u00f6rklund A. Striatal grafts in the ibotenic acid-lesioned neostriatum: Functional studies. Prog Brain Res  1988,78,39-45","journal-title":"Prog Brain Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/nm0898-963","volume":"4","author":"Palfi S.","year":"1998","unstructured":"Palfi S.; Cond\u00e9 F.; Riche D.; Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat Med  1998,4(8),963-966","journal-title":"Nat Med"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S0301-0082(99)00058-1","volume":"61","author":"Nakao N.","year":"2000","unstructured":"Nakao N.; Itakura T.; Fetal tissue transplants in animal models of Huntington\u2019s disease: The effects on damaged neuronal circuitry and behavioral deficits. Prog Neurobiol  2000,61(3),313-338","journal-title":"Prog Neurobiol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/0470870834.ch8","volume":"231","author":"Freeman T.B.","year":"2000","unstructured":"Freeman T.B.; Hauser R.A.; Willing A.E.; Zigova T.; Sanberg P.R.; Saporta S.; Transplantation of human fetal striatal tissue in Huntington\u2019s disease: Rationale for clinical studies. Novartis Found Symp  2000,231,129-138","journal-title":"Novartis Found Symp"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.3727\/096368912X657918","volume":"22","author":"Klein A.","year":"2013","unstructured":"Klein A.; Lane E.L.; Dunnett S.B.; Brain repair in a unilateral rat model of Huntington\u2019s disease: New insights into impairment and restoration of forelimb movement patterns. Cell Transplant  2013,22(10),1735-1751","journal-title":"Cell Transplant"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3727\/096368913X668636","volume":"23","author":"Cisbani G.","year":"2014","unstructured":"Cisbani G.; Saint-Pierre M.; Cicchetti F.; Single-cell suspension methodology favors survival and vascularization of fetal striatal grafts in the YAC128 mouse model of Huntington\u2019s disease. Cell Transplant  2014,23(10),1267-1278","journal-title":"Cell Transplant"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/mds.28201","volume":"35","author":"Bachoud-L\u00e9vi A.C.","year":"2020","unstructured":"Bachoud-L\u00e9vi A.C.; Human fetal cell therapy in Huntington\u2019s Disease: A randomized, multicenter, phase II trial. Mov Disord  2020,35(8),1323-1335","journal-title":"Mov Disord"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.3171\/jns.2000.93.6.1026","volume":"93","author":"Arnhold S.","year":"2000","unstructured":"Arnhold S.; Lenartz D.; Kruttwig K.; Differentiation of green fluorescent protein-labeled embryonic stem cell-derived neural precursor cells into Thy-1-positive neurons and glia after transplantation into adult rat striatum. J Neurosurg  2000,93(6),1026-1032","journal-title":"J Neurosurg"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/stem.177","volume":"27","author":"Nasonkin I.","year":"2009","unstructured":"Nasonkin I.; Mahairaki V.; Xu L.; Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. Stem Cells  2009,27(10),2414-2426","journal-title":"Stem Cells"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/74199","volume":"24","author":"Niwa H.","year":"2000","unstructured":"Niwa H.; Miyazaki J.; Smith A.G.; Quantitative expression of Oct-3\/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet  2000,24(4),372-376","journal-title":"Nat Genet"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/S0092-8674(03)00392-1","volume":"113","author":"Chambers I.","year":"2003","unstructured":"Chambers I.; Colby D.; Robertson M.; Nichols J.; Lee S.; Tweedie S.; Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell  2003,113(5),643-655","journal-title":"Cell"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"6031","DOI":"10.1128\/MCB.25.14.6031-6046.2005","volume":"25","author":"Chew J.L.","year":"2005","unstructured":"Chew J.L.; Loh Y.H.; Zhang W.; Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4\/Sox2 complex in embryonic stem cells. Mol Cell Biol  2005,25(14),6031-6046","journal-title":"Mol Cell Biol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.neuron.2015.02.001","volume":"85","author":"Michelsen K.A.","year":"2015","unstructured":"Michelsen K.A.; Acosta-Verdugo S.; Benoit-Marand M.; Area-specific reestablishment of damaged circuits in the adult cerebral cortex by cortical neurons derived from mouse embryonic stem cells. Neuron  2015,85(5),982-997","journal-title":"Neuron"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"Takahashi K.","year":"2006","unstructured":"Takahashi K.; Yamanaka S.; Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell  2006,126(4),663-676","journal-title":"Cell"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.cell.2008.07.041","volume":"134","author":"Park I.H.","year":"2008","unstructured":"Park I.H.; Arora N.; Huo H.; Disease-specific induced pluripotent stem cells. Cell  2008,134(5),877-886","journal-title":"Cell"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"RRN1193","DOI":"10.1371\/currents.RRN1193","volume":"2","author":"Zhang N.","year":"2010","unstructured":"Zhang N.; An M.C.; Montoro D.; Ellerby L.M.; Characterization of human Huntington\u2019s disease cell model from induced pluripotent stem cells. PLoS Curr  2010,2,RRN1193","journal-title":"PLoS Curr"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1042\/BJ20111495","volume":"446","author":"Chae J.I.","year":"2012","unstructured":"Chae J.I.; Kim D.W.; Lee N.; Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington\u2019s disease patient. Biochem J  2012,446(3),359-371","journal-title":"Biochem J"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1002\/stem.1135","volume":"30","author":"Jeon I.","year":"2012","unstructured":"Jeon I.; Lee N.; Li J.Y.; Neuronal properties, in vivo effects, and pathology of a Huntington\u2019s disease patient-derived induced pluripotent stem cells. Stem Cells  2012,30(9),2054-2062","journal-title":"Stem Cells"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"43","DOI":"10.15283\/ijsc.2014.7.1.43","volume":"7","author":"Jeon I.","year":"2014","unstructured":"Jeon I.; Choi C.; Lee N.; In vivo roles of a patient-derived induced pluripotent stem cell line (HD72-iPSC) in the YAC128 model of Huntington\u2019s disease. Int J Stem Cells  2014,7(1),43-47","journal-title":"Int J Stem Cells"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.stem.2012.04.026","volume":"11","author":"An M.C.","year":"2012","unstructured":"An M.C.; Zhang N.; Scott G.; Genetic correction of Huntington\u2019s disease phenotypes in induced pluripotent stem cells. Cell Stem Cell  2012,11(2),253-263","journal-title":"Cell Stem Cell"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13287-015-0248-1","volume":"6","author":"Kerkis I.","year":"2015","unstructured":"Kerkis I.; Haddad M.S.; Valverde C.W.; Glosman S.; Neural and mesenchymal stem cells in animal models of Huntington\u2019s disease: Past experiences and future challenges. Stem Cell Res Ther  2015,6(1),232","journal-title":"Stem Cell Res Ther"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.mcn.2007.11.001","volume":"37","author":"Bantubungi K.","year":"2008","unstructured":"Bantubungi K.; Blum D.; Cuvelier L.; Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington\u2019s disease. Mol Cell Neurosci  2008,37(3),454-470","journal-title":"Mol Cell Neurosci"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"e9347","DOI":"10.1371\/journal.pone.0009347","volume":"5","author":"Snyder B.R.","year":"2010","unstructured":"Snyder B.R.; Chiu A.M.; Prockop D.J.; Chan A.W.S.; Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington\u2019s disease. PLoS One  2010,5(2),e9347","journal-title":"PLoS One"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/scrt341","volume":"4","author":"Fink K.D.","year":"2013","unstructured":"Fink K.D.; Rossignol J.; Crane A.T.; Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6\/2 mice: Behavioral and neuropathological analysis. Stem Cell Res Ther  2013,4(5),130","journal-title":"Stem Cell Res Ther"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/ana.21788","volume":"66","author":"Lee S.T.","year":"2009","unstructured":"Lee S.T.; Chu K.; Jung K.H.; Slowed progression in models of huntington disease by adipose stem cell transplantation. Ann Neurol  2009,66(5),671-681","journal-title":"Ann Neurol"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"e22924","DOI":"10.1371\/journal.pone.0022924","volume":"6","author":"Lin Y.T.","year":"2011","unstructured":"Lin Y.T.; Chern Y.; Shen C.K.J.; Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington\u2019s disease mouse models. PLoS One  2011,6(8),e22924","journal-title":"PLoS One"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.scr.2012.05.005","volume":"9","author":"Moraes L.","year":"2012","unstructured":"Moraes L.; Vasconcelos-dos-Santos A.; Santana F.C.; Neuroprotective effects and magnetic resonance imaging of mesenchymal stem cells labeled with SPION in a rat model of Huntington\u2019s disease. Stem Cell Res (Amst)  2012,9(2),143-155","journal-title":"Stem Cell Res (Amst)"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1179\/016164110X12816242542571","volume":"33","author":"Jiang Y.","year":"2011","unstructured":"Jiang Y.; Lv H.; Huang S.; Tan H.; Zhang Y.; Li H.; Bone marrow mesenchymal stem cells can improve the motor function of a Huntington\u2019s disease rat model. Neurol Res  2011,33(3),331-337","journal-title":"Neurol Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.bbr.2010.11.006","volume":"217","author":"Rossignol J.","year":"2011","unstructured":"Rossignol J.; Boyer C.; L\u00e9v\u00e8que X.; Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington\u2019s disease: Morphological and behavioral outcomes. Behav Brain Res  2011,217(2),369-378","journal-title":"Behav Brain Res"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1242\/dev.116.1.201","volume":"116","author":"Mullen R.J.","year":"1992","unstructured":"Mullen R.J.; Buck C.R.; Smith A.M.; NeuN, a neuronal specific nuclear protein in vertebratesxs. Development  1992,116(1),201-211","journal-title":"Development"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1109967","DOI":"10.1155\/2023\/1109967","volume":"2023116","author":"Liang X.S.","year":"2023","unstructured":"Liang X.S.; Sun Z.W.; Thomas A.M.; Li S.; Mesenchymal stem cell therapy for Huntington Disease: A meta-analysis. Stem Cells Int  2023,2023116,1109967","journal-title":"Stem Cells Int"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/stem.1508","volume":"32","author":"Rossignol J.","year":"2014","unstructured":"Rossignol J.; Fink K.; Davis K.; Transplants of adult mesenchymal and neural stem cells provide neuroprotection and behavioral sparing in a transgenic rat model of Huntington\u2019s disease. Stem Cells  2014,32(2),500-509","journal-title":"Stem Cells"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14712598.2017.1365133","volume":"17","author":"Choi K.A.","year":"2017","unstructured":"Choi K.A.; Hong S.; Induced neural stem cells as a means of treatment in Huntington\u2019s disease. Expert Opin Biol Ther  2017,17(11),1-11","journal-title":"Expert Opin Biol Ther"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S0306-4522(98)00197-3","volume":"88","author":"Nakao N.","year":"1999","unstructured":"Nakao N.; Ogura M.; Nakai K.; Itakura T.; Embryonic striatal grafts restore neuronal activity of the globus pallidus in a rodent model of Huntington\u2019s disease. Neuroscience  1999,88(2),469-477","journal-title":"Neuroscience"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/jnr.21817","volume":"87","author":"Yang C.R.","year":"2009","unstructured":"Yang C.R.; Yu R.K.; Intracerebral transplantation of neural stem cells combined with trehalose ingestion alleviates pathology in a mouse model of Huntington\u2019s disease. J Neurosci Res  2009,87(1),26-33","journal-title":"J Neurosci Res"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"16707","DOI":"10.1073\/pnas.0808488105","volume":"105","author":"Aubry L.","year":"2008","unstructured":"Aubry L.; Bugi A.; Lefort N.; Rousseau F.; Peschanski M.; Perrier A.L.; Striatal progenitors derived from human ES cells mature into DARPP32 neurons in vitro and in quinolinic acid-lesioned rats. Proc Natl Acad Sci USA  2008,105(43),16707-16712","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cne.20176","volume":"475","author":"McBride J.L.","year":"2004","unstructured":"McBride J.L.; Behrstock S.P.; Chen E.Y.; Human neural stem cell transplants improve motor function in a rat model of Huntington\u2019s disease. J Comp Neurol  2004,475(2),211-219","journal-title":"J Comp Neurol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1007\/s00221-006-0689-y","volume":"177","author":"Johann V.","year":"2007","unstructured":"Johann V.; Schiefer J.; Sass C.; Time of transplantation and cell preparation determine neural stem cell survival in a mouse model of Huntington\u2019s disease. Exp Brain Res  2007,177(4),458-470","journal-title":"Exp Brain Res"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nbd.2004.01.016","volume":"16","author":"Ryu J.K.","year":"2004","unstructured":"Ryu J.K.; Kim J.; Cho S.J.; Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis  2004,16(1),68-77","journal-title":"Neurobiol Dis"},{"key":"ref=167","unstructured":"ClinicalTrials.gov. Available From","journal-title":"Available From"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/brain\/awac086","volume":"145","author":"Rosser A.E.","year":"2022","unstructured":"Rosser A.E.; Busse M.E.; Gray W.P.; Translating cell therapies for neurodegenerative diseases: Huntington\u2019s disease as a model disorder. Brain  2022,145(5),1584-1597","journal-title":"Brain"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.brainresbull.2019.05.024","volume":"150","author":"Puhl D.L.","year":"2019","unstructured":"Puhl D.L.; D\u2019Amato A.R.; Gilbert R.J.; Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors. Brain Res Bull  2019,150,216-230","journal-title":"Brain Res Bull"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1089\/hum.2020.105","volume":"32","author":"Piguet F.","year":"2021","unstructured":"Piguet F.; de Saint Denis T.; Audouard E.; The challenge of gene therapy for neurological diseases: Strategies and tools to achieve efficient delivery to the central nervous system. Hum Gene Ther  2021,32(7-8),349-374","journal-title":"Hum Gene Ther"},{"key":"ref=171","first-page":"159","author":"Lelos M.J.","year":"2022","unstructured":"Lelos M.J.;  Investigating cell therapies in animal models of Parkinson\u2019s and Huntington\u2019s disease: Current challenges and considerations International Review of Neurobiology  2022,159-189","journal-title":"Investigating cell therapies in animal models of Parkinson\u2019s and Huntington\u2019s disease: Current challenges and considerations International Review of Neurobiology"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/sj.gt.3303048","volume":"15","author":"Shen F.","year":"2008","unstructured":"Shen F.; Fan Y.; Su H.; Adeno-associated viral vector-mediated hypoxia-regulated VEGF gene transfer promotes angiogenesis following focal cerebral ischemia in mice. Gene Ther  2008,15(1),30-39","journal-title":"Gene Ther"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7150\/ijms.1.76","volume":"1","author":"Smith K.R.","year":"2004","unstructured":"Smith K.R.; Gene therapy: The potential applicability of gene transfer technology to the human germline. Int J Med Sci  2004,1(2),76-91","journal-title":"Int J Med Sci"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/sj.gt.3301946","volume":"10","author":"Gore M.E.","year":"2003","unstructured":"Gore M.E.; Adverse effects of gene therapy: Gene therapy can cause leukaemia: No shock, mild horror but a probe. Gene Ther  2003,10(1),4","journal-title":"Gene Ther"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.ymthe.2017.03.018","volume":"25","author":"Thrasher A.J.","year":"2017","unstructured":"Thrasher A.J.; Williams D.A.; Evolving gene therapy in primary immunodeficiency. Mol Ther  2017,25(5),1132-1141","journal-title":"Mol Ther"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1080\/1061186X.2019.1630415","volume":"28","author":"Pena S.A.","year":"2020","unstructured":"Pena S.A.; Iyengar R.; Eshraghi R.S.; Gene therapy for neurological disorders: Challenges and recent advancements. J Drug Target  2020,28(2),111-128","journal-title":"J Drug Target"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nrg1066","volume":"4","author":"Thomas C.E.","year":"2003","unstructured":"Thomas C.E.; Ehrhardt A.; Kay M.A.; Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet  2003,4(5),346-358","journal-title":"Nat Rev Genet"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nbt.1807","volume":"29","author":"Alvarez-Erviti L.","year":"2011","unstructured":"Alvarez-Erviti L.; Seow Y.; Yin H.; Betts C.; Lakhal S.; Wood M.J.A.; Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol  2011,29(4),341-345","journal-title":"Nat Biotechnol"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"19579","DOI":"10.1038\/srep19579","volume":"6","author":"Fan C.H.","year":"2016","unstructured":"Fan C.H.; Ting C.Y.; Lin C.Y.; Noninvasive, Targeted and Non-Viral Ultrasound-Mediated GDNF-Plasmid Delivery for Treatment of Parkinson\u2019s Disease. Sci Rep  2016,6(1),19579","journal-title":"Sci Rep"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/sj.gt.3302135","volume":"11","author":"Li Y.","year":"2004","unstructured":"Li Y.; Wang J.; Lee C.G.L.; CNS gene transfer mediated by a novel controlled release system based on DNA complexes of degradable polycation PPE-EA: A comparison with polyethylenimine\/DNA complexes. Gene Ther  2004,11(1),109-114","journal-title":"Gene Ther"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11481-016-9724-3","volume":"12","author":"Joshi C.R.","year":"2017","unstructured":"Joshi C.R.; Labhasetwar V.; Ghorpade A.; Destination brain: The past, present, and future of therapeutic gene delivery. J Neuroimmune Pharmacol  2017,12(1),51-83","journal-title":"J Neuroimmune Pharmacol"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"van Tellingen O.","year":"2015","unstructured":"van Tellingen O.; Yetkin-Arik B.; de Gooijer M.C.; Wesseling P.; Wurdinger T.; de Vries H.E.; Overcoming the blood\u2013brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat  2015,19,1-12","journal-title":"Drug Resist Updat"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.281.5373.78","volume":"281","author":"Koltover I.","year":"1998","unstructured":"Koltover I.; Salditt T.; R\u00e4dler JO.; Safinya CR.; An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science  1998,281(5373),78-81","journal-title":"Science"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nature05901","volume":"448","author":"Kumar P.","year":"2007","unstructured":"Kumar P.; Wu H.; McBride J.L.; Transvascular delivery of small interfering RNA to the central nervous system. Nature  2007,448(7149),39-43","journal-title":"Nature"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425247.5.1.105","volume":"5","author":"Foged C.","year":"2008","unstructured":"Foged C.; Nielsen H.M.; Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv  2008,5(1),105-117","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3389\/fncel.2020.00250","volume":"14","author":"Salado-Manzano C","year":"2020","unstructured":"Salado-Manzano C;  Perpi\u00f1a U, Straccia M, et al. Is the immunological response a bottleneck for cell therapy in neurodegenerative diseases? Front Cell Neurosci  2020,14,250","journal-title":"Front Cell Neurosci"},{"key":"ref=187","first-page":"235","author":"Drew C.J.G.","year":"2022","unstructured":"Drew C.J.G.; Busse M.;  Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease International Review of Neurobiology  2022,235-279","journal-title":"Considerations for clinical trial design and conduct in the evaluation of novel advanced therapeutics in neurodegenerative disease International Review of Neurobiology"},{"key":"ref=188","year":"2008","unstructured":"European Medicines Agency. Guideline on human cell-based medicinal products.  Available From\n https:\/\/www.ema. europa.eu\/en\/documents\/scientific-guideline\/guideline-human-cell-based-medicinal-products_en.pdf2008"},{"key":"ref=189","year":"2015","unstructured":"Food and Drug Administration. Human cells, tissues, and cellular and tissue-based products.  Available From\n https:\/\/www.federalregister.gov\/documents\/2001\/01\/19\/01-1126\/human-cells-tissues-and-cellular-and-tissue-based-products-establishment-registration-and-listing2015"},{"key":"ref=190","year":"2003","unstructured":"Food and Drug Administration, Guidance for FDA reviewers and sponsors.  Available From  https:\/\/www.fda.gov\/media\/73624\/download2003"},{"key":"ref=191","year":"1997","unstructured":"Food and Drug Administration. Proposed approach to regulation of cellular and tissue-based products.  Available From\n https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/proposed-approach-regulation-cellular-and-tissue-based-products\n1997"},{"key":"ref=192","year":"2010","unstructured":"European Medicines Agency. Reflection paper on stem cell-based medicinal products.  Available From\n https:\/\/www.ema. europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-stem-cell-based-medicinal-products_en.pdf\n2010"},{"key":"ref=193","year":"2008","unstructured":"International Society for Stem Cell Research. Guidelines for the clinical translation of stem cells.  Available From\n https:\/\/www.isscr.org\/guidelines\n2008"},{"key":"ref=194","year":"2008","unstructured":"Food and Drug Administration. CTGTAC Meeting # 45. Cellular therapies derived from human embryonic stem cells \u2013 Considerations for pre-clinical safety testing and patient monitoring.  2008"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00103-009-0992-4","volume":"53","author":"Klug B.","year":"2010","unstructured":"Klug B.; Reinhardt J.; Schr\u00f6der C.; Requirements for long-term follow-up on efficacy and safety of advanced therapy medicinal products. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz  2010,53(1),58-62","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1073\/pnas.0501507102","volume":"102","author":"Harper S.Q.","year":"2005","unstructured":"Harper S.Q.; Staber P.D.; He X.; RNA interference improves motor and neuropathological abnormalities in a Huntington\u2019s disease mouse model. Proc Natl Acad Sci USA  2005,102(16),5820-5825","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.omtn.2019.07.009","volume":"17","author":"Ekman F.K.","year":"2019","unstructured":"Ekman F.K.; Ojala D.S.; Adil M.M.; Lopez P.A.; Schaffer D.V.; Gaj T.; CRISPR-Cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington\u2019s disease mouse model. Mol Ther Nucleic Acids  2019,17,829-839","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.apsb.2020.01.015","volume":"10","author":"Chen W.","year":"2020","unstructured":"Chen W.; Hu Y.; Ju D.; Gene therapy for neurodegenerative disorders: Aadvances, insights and prospects. Acta Pharm Sin B  2020,10(8),1347-1359","journal-title":"Acta Pharm Sin B"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","volume":"101","author":"Tabrizi S.J.","year":"2019","unstructured":"Tabrizi S.J.; Ghosh R.; Leavitt B.R.; Huntingtin lowering strategies for disease modification in Huntington\u2019s disease. Neuron  2019,101(5),801-819","journal-title":"Neuron"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1002\/jnr.24845","volume":"99","author":"Beatriz M.","year":"2021","unstructured":"Beatriz M.; Lopes C.; Ribeiro A.C.S.; Rego A.C.C.; Revisiting cell and gene therapies in Huntington\u2019s disease. J Neurosci Res  2021,99(7),1744-1762","journal-title":"J Neurosci Res"},{"key":"ref=201","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.102539","author":"Kerkis I.","year":"2022","unstructured":"Kerkis I.; Araldi R.P.; Wenceslau C.V.; Mendes T.B.;  Advances in cellular and cell-free therapy medicinal products for Huntington disease treatmentFrom Pathophysiology to Treatment of Huntington\u2019s Disease  2022","journal-title":"Advances in cellular and cell-free therapy medicinal products for Huntington disease treatmentFrom Pathophysiology to Treatment of Huntington\u2019s Disease"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"110673","DOI":"10.1016\/j.brainresbull.2023.110673","volume":"199","author":"Conner L.T.","year":"2023","unstructured":"Conner L.T.; Srinageshwar B.; Bakke J.L.; Dunbar G.L.; Rossignol J.; Advances in stem cell and other therapies for Huntington\u2019s disease: An update. Brain Res Bull  2023,199,110673","journal-title":"Brain Res Bull"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.tins.2023.02.005","volume":"46","author":"Duan W.","year":"2023","unstructured":"Duan W.; Urani E.; Mattson M.P.; The potential of gene editing for Huntington\u2019s disease. Trends Neurosci  2023,46(5),365-376","journal-title":"Trends Neurosci"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/stem.3300","volume":"39","author":"Bachoud-L\u00e9vi A.C.","year":"2021","unstructured":"Bachoud-L\u00e9vi A.C.; Massart R.; Rosser A.; Cell therapy in Huntington\u2019s disease: Taking stock of past studies to move the field forward. Stem Cells  2021,39(2),144-155","journal-title":"Stem Cells"}],"container-title":["Current Reviews in Clinical and Experimental Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328300166240510071548","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/230268\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0127724328300166240510071548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T13:36:42Z","timestamp":1733751402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/230268\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":204,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0127724328300166240510071548","relation":{},"ISSN":["2772-4328"],"issn-type":[{"value":"2772-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}